Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Ziprasidone
Overview
What is Ziprasidone?
Ziprasidone is available as capsules (ziprasidone hydrochloride) for oral administration. Ziprasidone is a psychotropic agent that is chemically unrelated to phenothiazine or butyrophenone antipsychotic agents. It has a molecular weight of 412.94 (free base), with the following chemical name: 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2-indol-2-one. The molecular formula of CHClNOS (free base of ziprasidone) represents the following structural formula:
Ziprasidone hydrochloride capsules contain a monohydrochloride, monohydrate salt of ziprasidone. Chemically, ziprasidone hydrochloride monohydrate is 5-[2-[4-(1,2 benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2-indol-2-one, monohydrochloride, monohydrate. The molecular formula is CHClNOS · HCl · HO and its molecular weight is 467.42.
Ziprasidone hydrochloride monohydrate, USP is white to slightly pink powder; slightly soluble in methanol, methylene chloride, isopropyl alcohol and hot tetrahydrofuran, soluble in formic acid and practically insoluble in water and ethanol.
Each capsule contains ziprasidone hydrochloride monohydrate 20 mg or 40 mg or 60 mg or 80 mg and inactive ingredients: gelatin, lactose monohydrate, magnesium stearate, pregelatinized starch (botanical source: maize), sodium lauryl sulfate, titanium dioxide, water, FD & C Blue 1 (20 mg, 40 mg and 80 mg) and FD & C Red 40 (20 mg, 40 mg and 80 mg). Additionally capsule shells of 20 mg, 40 mg and 80 mg are imprinted with white pharmaceutical ink and capsule shells of 60 mg are imprinted with black pharmaceutical ink. The compositions of the black and white pharmaceutical ink are: butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, strong ammonia solution, titanium dioxide and ferrosoferric oxide (black pharmaceutical ink).
What does Ziprasidone look like?
What are the available doses of Ziprasidone?
Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body.
Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with '238' in white ink and a dark blue opaque body.
Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body.
Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body.
What should I talk to my health care provider before I take Ziprasidone?
How should I use Ziprasidone?
Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia.
When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [)]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [ ]
Dose Selection
Ziprasidone hydrochloride capsules should be administered at an initial daily dose of 20 mg twice daily with food. In some patients, daily dosage may subsequently be adjusted on the basis of individual clinical status up to 80 mg twice daily. Dosage adjustments, if indicated, should generally occur at intervals of not less than 2 days, as steady-state is achieved within 1 to 3 days. In order to ensure use of the lowest effective dose, patients should ordinarily be observed for improvement for several weeks before upward dosage adjustment.
Efficacy in schizophrenia was demonstrated in a dose range of 20 mg to 100 mg twice daily in short-term, placebo-controlled clinical trials. There were trends toward dose response within the range of 20 mg to 80 mg twice daily, but results were not consistent. An increase to a dose greater than 80 mg twice daily is not generally recommended. The safety of doses above 100 mg twice daily has not been systematically evaluated in clinical trials [].
Maintenance Treatment
While there is no body of evidence available to answer the question of how long a patient treated with ziprasidone should remain on it, a maintenance study in patients who had been symptomatically stable and then randomized to continue ziprasidone or switch to placebo demonstrated a delay in time to relapse for patients receiving ziprasidone []. No additional benefit was demonstrated for doses above 20 mg twice daily. Patients should be periodically reassessed to determine the need for maintenance treatment.
What interacts with Ziprasidone?
Sorry No Records found
What are the warnings of Ziprasidone?
Sorry No Records found
What are the precautions of Ziprasidone?
Sorry No Records found
What are the side effects of Ziprasidone?
Sorry No records found
What should I look out for while using Ziprasidone?
Do not use in patients with a known history of QT prolongation ()
Do not use in patients with recent acute myocardial infarction ()
Do not use in patients with uncompensated heart failure ()
Do not use in combination with other drugs that have demonstrated QT prolongation ()
What might happen if I take too much Ziprasidone?
How should I store and handle Ziprasidone?
StorageStore Pantoprazole Sodium Delayed-Release Tablets, USP at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [ ]. StorageStore Pantoprazole Sodium Delayed-Release Tablets, USP at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [ ]. Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Ziprasidone hydrochloride capsules, 20 mg are white to slightly pink granular powder filled in size '4' hard gelatin capsules having a dark blue opaque cap printed with '237' in white ink and a white opaque body and are supplied as:NDC 70771-1179-6 in bottle of 60 capsulesNDC 70771-1179-5 in bottle of 500 capsulesNDC 70771-1179-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 40 mg are white to slightly pink granular powder filled in size '3' hard gelatin capsules having a dark blue opaque cap printed with'238' in white ink and a dark blue opaque body and are supplied as:NDC 70771-1180-6 in bottle of 60 capsulesNDC 70771-1180-5 in bottle of 500 capsulesNDC 70771-1180-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 60 mg are white to slightly pink granular powder filled in size '2' hard gelatin capsules having a white opaque cap printed with '239' in black ink and a white opaque body and are supplied as:NDC 70771-1181-6 in bottle of 60 capsulesNDC 70771-1181-5 in bottle of 500 capsulesNDC 70771-1181-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules, 80 mg are white to slightly pink granular powder filled in size '1' hard gelatin capsules having a dark blue opaque cap printed with '240' in white ink and a light blue opaque body and are supplied as:NDC 70771-1182-6 in bottle of 60 capsulesNDC 70771-1182-5 in bottle of 500 capsulesNDC 70771-1182-8 in cartons of 80 capsules (8 x 10 unit-dose)Ziprasidone hydrochloride capsules should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
The mechanism of action of ziprasidone, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug's efficacy in schizophrenia is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism.
Non-Clinical Toxicology
Do not use in patients with a known history of QT prolongation ()Do not use in patients with recent acute myocardial infarction ()
Do not use in patients with uncompensated heart failure ()
Do not use in combination with other drugs that have demonstrated QT prolongation ()
Life-Threatening Respiratory Depression
Discuss the risk of respiratory depression with patients, explaining that the risk is greatest when starting methadone hydrochloride oral concentrate or when the dose is increased . Advise patients how to recognize respiratory depression and to seek medical attention if they are experiencing breathing difficulties.
Symptoms of Arrhythmia
Instruct patients to seek medical attention immediately if they experience symptoms suggestive of an arrhythmia (such as palpitations, near syncope, or syncope) when taking methadone hydrochloride oral concentrate.
Accidental Ingestion
Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death . Instruct patients to take steps to store methadone hydrochloride oral concentrate securely. Advise patients to dispose of unused methadone hydrochloride oral concentrate by flushing down the toilet.
Abuse Potential
Inform patients that methadone hydrochloride oral concentrate contains methadone, a Schedule II controlled substance that is subject to abuse . Instruct patients not to share methadone hydrochloride oral concentrate with others and to take steps to protect methadone hydrochloride oral concentrate from theft or misuse.
Risks from Concomitant Use of Alcohol and other CNS Depressants
Inform patients that the concomitant use of alcohol with methadone can increase the risk of life-threatening respiratory depression. Instruct patients not to consume alcoholic beverages, as well as prescription and over-the-counter drug products that contain alcohol, during treatment with methadone hydrochloride oral concentrate .
Inform patients that potentially serious additive effects may occur if methadone is used with other CNS depressants, and not to use such drugs unless supervised by a health care provider.
Instruct patients how to properly take methadone hydrochloride oral concentrate, including the following:
Serotonin Syndrome:
Inform patients that methadone hydrochloride oral concentrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their physicians if they are taking, or plan to take serotonergic medications (see and ).
MAOI Interaction
Inform patients to avoid taking methadone hydrochloride oral concentrate while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking methadone hydrochloride oral concentrate .
Adrenal Insufficiency:
Inform patients that methadone hydrochloride oral concentrate could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms.
Anaphylaxis
Inform patients that anaphylaxis has been reported with ingredients contained in methadone hydrochloride oral concentrate. Advise patients how to recognize such a reaction and when to seek medical attention .
Neonatal Opioid Withdrawal
Advise women that if they are pregnant while being treated with methadone hydrochloride oral concentrate, the baby may have signs of withdrawal at birth and that withdrawal is treatable.
Lactation
Instruct nursing mothers using methadone hydrochloride oral concentrate to watch for signs of methadone toxicity in their infants, which include increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to their baby’s healthcare provider immediately if they notice these signs. If they cannot reach the healthcare provider right away, instruct them to take the baby to the emergency room or call 911 (or local emergency services) .
Constipation
Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention .
ID357
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone is not approved for the treatment of dementia-related psychosis.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
517Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).